Bank Julius Baer & Co
CDTX

Bank Julius Baer & Co’s Cidara Therapeutics CDTX Stock Holding History

Bank Julius Baer & Co’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-650
Closed -$37K – 810
2020
Q3 		$37K Hold
650
– – ﹤0.01% 626
2020
Q2 		$48K Buy
650
+343
+112% +$22.2K ﹤0.01% 570
2020
Q1 		$15K Buy
+307
New +$18.4K ﹤0.01% 589

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank Julius Baer & Co's CDTX Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of Cidara Therapeutics (CDTX) in Q4 2020, closing a stake of 650 shares — an estimated $37K sold.

Bank Julius Baer & Co first reported a position in CDTX in Q1 2020 and held it in 3 quarters. The position peaked at $48K in Q2 2020. 63 funds tracked by Wall St. Rank hold CDTX as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining Cidara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 650 Cidara Therapeutics shares in Q4 2020, an estimated $37K.
  • Bank Julius Baer & Co first reported a position in Cidara Therapeutics in Q1 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Cidara Therapeutics position peaked at $48K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.